Overexpression of FAK and p-FAK in numerous cancers indicates that targeting FAK might be effective in suppressing biological capacities required for tumorigenesis which makes it an attractive drug target for anti-cancer therapy (Sharma et al., 2017; Pomella et al., 2022). This evidence concerns the gene PTK2 and cancer.